Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML… Read more
Vor Biopharma Inc (VOR) - Total Assets
Latest total assets as of September 2025: $176.24 Million USD
Based on the latest financial reports, Vor Biopharma Inc (VOR) holds total assets worth $176.24 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vor Biopharma Inc - Total Assets Trend (2018–2024)
This chart illustrates how Vor Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vor Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Vor Biopharma Inc's total assets of $176.24 Million consist of 67.5% current assets and 32.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Vor Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vor Biopharma Inc's current assets represent 67.5% of total assets in 2024, a decrease from 93.0% in 2018.
- Cash Position: Cash and equivalents constituted 57.4% of total assets in 2024, down from 92.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vor Biopharma Inc Competitors by Total Assets
Key competitors of Vor Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vor Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vor Biopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vor Biopharma Inc is currently not profitable relative to its asset base.
Vor Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.16 | 4.69 | 4.81 |
| Quick Ratio | 9.16 | 4.69 | 4.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $153.65 Million | $ 52.95 Million | $ 38.90 Million |
Vor Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Vor Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -31.9% |
| Total Assets | $142.89 Million |
| Market Capitalization | $98.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vor Biopharma Inc's assets below their book value (0.69 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vor Biopharma Inc's assets decreased by 31.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vor Biopharma Inc (2018–2024)
The table below shows the annual total assets of Vor Biopharma Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $142.89 Million | -31.90% |
| 2023-12-31 | $209.83 Million | -29.91% |
| 2022-12-31 | $299.37 Million | +23.40% |
| 2021-12-31 | $242.59 Million | +219.58% |
| 2020-12-31 | $75.91 Million | +672.52% |
| 2019-12-31 | $9.83 Million | +875.77% |
| 2018-12-31 | $1.01 Million | -- |